Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025).
Overview
- Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai, China
- Shanghai Frontiers Science Center of Nanocatalytic Medicine, Tongji University, Shanghai, China
- Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Clinical Research Center for Anesthesiology and Perioperative Medicine, Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People’s Hospital Affiliated to Tongji University School of Medicine, Shanghai Research Institute for Intelligent Autonomous Systems, State Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
Abstract
Amyotrophic lateral sclerosis (ALS) remains a major therapeutic challenge, with immune dysregulation increasingly recognized as a critical driver of disease progression. Despite extensive mechanistic research, no immunotherapeutic approach has achieved consistent disease-modifying effects, raising questions about whether this translational gap reflects biological complexity or structural misalignment within the research ecosystem. To characterize the intellectual evolution of ALS immunotherapeutics research, identify immune targets with translational potential, and evaluate collaboration patterns that may influence translational efficiency, we performed a bibliometric analysis of 2,256 publications indexed in Web of Science and Scopus using network-based approaches including co-citation clustering, keyword co-occurrence, and citation burst detection implemented in CiteSpace, VOSviewer, and R-Bibliometrix. Publication output increased 8.4-fold over the study period, delineating three developmental phases. Thematic analyses revealed a shift from early emphasis on microglial biology and SOD1-based models toward recent focus areas including the gut–brain axis, C9orf72-associated immune dysregulation, and advanced immunomodulatory strategies. Collaboration networks remain predominantly regional despite strong contributions from the United States, Europe, and Asia, with limited integration between mechanistic research groups and clinical trial consortia. Among immune-directed therapeutic strategies, regulatory T cell modulation and microglial-targeted approaches exhibit the highest translational readiness. These findings suggest that the lack of effective ALS immunotherapeutics reflects not only biological complexity but also structural and strategic misalignment within the research ecosystem. This bibliometric analysis provides a systems-level framework to guide more integrated translational strategies in ALS immunotherapeutics development.
Reproduced under the paper's license (CC BY-NC), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- figshare:32337413, at figshare; found in DataCite
Data availability statement
The data presented in this study are available on request from the corresponding author.
Reproduced under the paper's license (CC BY-NC), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 2, 28 September 2026
- Funding: added National Natural Science Foundation of China: 82471448; Science and Technology Commission of Shanghai Municipality: 24ZR1468500; Fundamental Research Funds for the Central Universities: 22120240333
Version 1, 28 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 7 authors, 6 keywords, 9 MeSH terms, 69 references.
Cite
This paper
Zhang, M., Yang, W., Wang, J., Zou, B., Zheng, J. C., Wu, Q., & Gao, G. (2026). Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025). Human vaccines & immunotherapeutics, 22(1), 2664985. https://
BibTeX
@article{zhang2026immuno
author = {Zhang, Ming and Yang, Wenshuo and Wang, Junxin and Zou, Biqi and Zheng, Jialin C and Wu, Qihui and Gao, Ge},
title = {{Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025)}},
journal = {Human vaccines \& immunotherapeutics},
year = {2026},
month = may,
volume = {22},
number = {1},
pages = {2664985},
publisher = {Taylor \& Francis},
issn = {2164-5515},
doi = {10.1080/
url = {https://
pmid = {42160515},
pmcid = {PMC13196659}
}
RIS
TY - JOUR
AU - Zhang, Ming
AU - Yang, Wenshuo
AU - Wang, Junxin
AU - Zou, Biqi
AU - Zheng, Jialin C
AU - Wu, Qihui
AU - Gao, Ge
TI - Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025)
T2 - Human vaccines & immunotherapeutics
J2 - Hum Vaccin Immunother
PY - 2026
DA - 2026/
VL - 22
IS - 1
SP - 2664985
SN - 2164-5515
PB - Taylor & Francis
DO - 10.1080/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1080/
"type": "article-journal",
"title": "Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025)",
"container-title": "Human vaccines & immunotherapeutics",
"author": [
{
"family": "Zhang",
"given": "Ming"
},
{
"family": "Yang",
"given": "Wenshuo"
},
{
"family": "Wang",
"given": "Junxin"
},
{
"family": "Zou",
"given": "Biqi"
},
{
"family": "Zheng",
"given": "Jialin C"
},
{
"family": "Wu",
"given": "Qihui"
},
{
"family": "Gao",
"given": "Ge"
}
],
"container-title-short":
"volume": "22",
"issue": "1",
"page": "2664985",
"DOI": "10.1080/
"PMID": "42160515",
"PMCID": "PMC13196659",
"ISSN": "2164-5515",
"publisher": "Taylor & Francis",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
5,
20
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1038/s41573-022-00612-2
- Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation.Journal: Nature reviews. Drug discoveryIn common: clinical / translational, other condition, 5 references
- [2] doi:10.1038/s41593-026-02300-5 [code]
- Integrated single-cell and spatial transcriptomic profiling in ALS uncovers peripheral-to-central immune infiltration and reprogramming.Journal: Nature neuroscienceIn common: other condition, 4 references
- [3] doi:10.3389/fimmu.2025.1662197 [code]
- Tofacitinib extends survival in a mouse model of ALS through NK cell-independent mechanisms.Journal: Frontiers in immunologyIn common: other condition, 3 references
- [4] doi:10.1038/s42003-025-08578-8
- Machine learning-based proteomics profiling of ALS identifies downregulation of RPS29 that maintains protein homeostasis and STMN2 level.Journal: Communications biologyIn common: other condition, 3 references
- [5] doi:10.3389/fnins.2025.1598336
- A systematic review and functional &
lt;i& gt;in-silico& lt;/ i& gt; analysis of genes and variants associated with amyotrophic lateral sclerosis. Journal: Frontiers in neuroscienceIn common: other condition, 3 references - [6] doi:10.1038/s41467-023-40917-3 [code]
- At-home wearables and machine learning sensitively capture disease progression in amyotrophic lateral sclerosis.Journal: Nature communicationsIn common: clinical / translational, other condition, 2 references
- [7] doi:10.1016/j.omtm.2024.101312
- Combination AAV therapy with galectin-1 and SOD1 downregulation demonstrates superior therapeutic effect in a severe ALS mouse model.Journal: Molecular therapy. Methods & clinical developmentIn common: clinical / translational, other condition, 2 references
- [8] doi:10.1038/s41586-025-09588-6
- Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.Journal: NatureIn common: other condition, 2 references
- [9] doi:10.3389/fphar.2022.946548
- Herbal medicine for amyotrophic lateral sclerosis: A systematic review and meta-analysis.Journal: Frontiers in pharmacologyIn common: clinical / translational, other condition, 2 references
- [10] doi:10.3389/fnagi.2025.1735522
- Exploring rare coding variants in UK biobank: preliminary associations with motor neuron disease.Journal: Frontiers in aging neuroscienceIn common: other condition, 2 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
